Patient characteristics
| Patient characteristics . | Initial vaccination (n = 202), n (%) . | Booster vaccination (n = 114), n (%) . | |
|---|---|---|---|
| Gender | |||
| Female | 85 (42) | 43 (38) | |
| Male | 117 (58) | 71 (62) | |
| Race | |||
| White | 179 (89) | 100 (88) | |
| Asian | 4 (2) | 1 (0) | |
| American Indian/Alaska native | 1 (0.5) | 0 (0) | |
| Black | 1 (0.5) | 2 (2) | |
| Unknown/not reported | 17 (8) | 11 (10) | |
| Age (y) | |||
| Median | 65 | 65 | |
| Range | 31-88 | 39-88 | |
| Y since diagnosis | |||
| Median | 7 | 5 | |
| Range | 1-30 | 0-26 | |
| Vaccine | Initial: | Booster: | |
| BNT162b2 | 128 (63) | 76 (67) | 81 (71) |
| mRNA-1273 | 66 (33) | 32 (28) | 29 (25) |
| Ad26.COV2.S | 8 (4) | 6 (5) | 4 (4) |
| Absolute lymphocyte count | |||
| Median | 2.96 × 103/μL | 5.06 × 103/μL | |
| Range | 0.21 × 103/μL-173.4 × 103/μL | 0.25 × 103/μL-137 × 103/μL | |
| FISH | |||
| Del 13q | 70 (35) | 34 (30) | |
| Normal | 36 (18) | 19 (16) | |
| Trisomy 12 | 35 (17) | 20 (16) | |
| Del 11q | 16 (8) | 11 (9) | |
| Del 17p | 17 (8) | 10 (9) | |
| Unknown | 28 (14) | 23 (20) | |
| Rai stage | |||
| 0 | 46 (23) | 23 (20) | |
| 1 | 47 (23) | 30 (26) | |
| 2 | 24 (12) | 17 (15) | |
| 3 | 10 (5) | 6 (5) | |
| 4 | 21 (10) | 11 (10) | |
| Unknown | 54 (27) | 27 (24) | |
| IGHV status | |||
| Mutated | 58 (29) | 23 (20) | |
| Unmutated | 88 (44) | 31 (27) | |
| Unknown | 56 (27) | 60 (53) | |
| Treatment-naïve | |||
| No | 131 (65) | 70 (61) | |
| Yes | 71 (35) | 44 (39) | |
| Type of CLL directed therapy | |||
| None | 118 (58) | 63 (55) | |
| BTK inhibitor | 41 (20) | 29 (25) | |
| Venetoclax | 5 (3) | 2 (2) | |
| Venetoclax + CD20 Mab | 13 (7) | 7 (6) | |
| BTK inhibitor + CD20 Mab | 7 (3) | 5 (4) | |
| BTK inhibitor + venetoclax | 8 (4) | 4 (4) | |
| BTK inhibitor + venetoclax + CD20 | 2 (1) | 3 (3) | |
| Mab | 8 (4) | 1 (1) | |
| Other | |||
| Months from CD20 Mab exposure | |||
| On treatment - 6 mo | 27 (13) | 12 (11) | |
| 7 to 12 mo | 10 (5) | 6 (5) | |
| >12 mo | 55 (27) | 30 (26) | |
| No exposure | 110 (54) | 66 (58) | |
| Patient characteristics . | Initial vaccination (n = 202), n (%) . | Booster vaccination (n = 114), n (%) . | |
|---|---|---|---|
| Gender | |||
| Female | 85 (42) | 43 (38) | |
| Male | 117 (58) | 71 (62) | |
| Race | |||
| White | 179 (89) | 100 (88) | |
| Asian | 4 (2) | 1 (0) | |
| American Indian/Alaska native | 1 (0.5) | 0 (0) | |
| Black | 1 (0.5) | 2 (2) | |
| Unknown/not reported | 17 (8) | 11 (10) | |
| Age (y) | |||
| Median | 65 | 65 | |
| Range | 31-88 | 39-88 | |
| Y since diagnosis | |||
| Median | 7 | 5 | |
| Range | 1-30 | 0-26 | |
| Vaccine | Initial: | Booster: | |
| BNT162b2 | 128 (63) | 76 (67) | 81 (71) |
| mRNA-1273 | 66 (33) | 32 (28) | 29 (25) |
| Ad26.COV2.S | 8 (4) | 6 (5) | 4 (4) |
| Absolute lymphocyte count | |||
| Median | 2.96 × 103/μL | 5.06 × 103/μL | |
| Range | 0.21 × 103/μL-173.4 × 103/μL | 0.25 × 103/μL-137 × 103/μL | |
| FISH | |||
| Del 13q | 70 (35) | 34 (30) | |
| Normal | 36 (18) | 19 (16) | |
| Trisomy 12 | 35 (17) | 20 (16) | |
| Del 11q | 16 (8) | 11 (9) | |
| Del 17p | 17 (8) | 10 (9) | |
| Unknown | 28 (14) | 23 (20) | |
| Rai stage | |||
| 0 | 46 (23) | 23 (20) | |
| 1 | 47 (23) | 30 (26) | |
| 2 | 24 (12) | 17 (15) | |
| 3 | 10 (5) | 6 (5) | |
| 4 | 21 (10) | 11 (10) | |
| Unknown | 54 (27) | 27 (24) | |
| IGHV status | |||
| Mutated | 58 (29) | 23 (20) | |
| Unmutated | 88 (44) | 31 (27) | |
| Unknown | 56 (27) | 60 (53) | |
| Treatment-naïve | |||
| No | 131 (65) | 70 (61) | |
| Yes | 71 (35) | 44 (39) | |
| Type of CLL directed therapy | |||
| None | 118 (58) | 63 (55) | |
| BTK inhibitor | 41 (20) | 29 (25) | |
| Venetoclax | 5 (3) | 2 (2) | |
| Venetoclax + CD20 Mab | 13 (7) | 7 (6) | |
| BTK inhibitor + CD20 Mab | 7 (3) | 5 (4) | |
| BTK inhibitor + venetoclax | 8 (4) | 4 (4) | |
| BTK inhibitor + venetoclax + CD20 | 2 (1) | 3 (3) | |
| Mab | 8 (4) | 1 (1) | |
| Other | |||
| Months from CD20 Mab exposure | |||
| On treatment - 6 mo | 27 (13) | 12 (11) | |
| 7 to 12 mo | 10 (5) | 6 (5) | |
| >12 mo | 55 (27) | 30 (26) | |
| No exposure | 110 (54) | 66 (58) | |
IGHV, immunoglobulin heavy chain variable region gene.